A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives
Richard L. Schilsky, MD
Jennifer Malin, MD
Michael Kolodziej, MD
James C. Robinson
Designed to pay for breakthroughs, the new technology add-on (NTAP) ‘bump’ is also too unpredictable, say drug and device groups.
Childhood cancer hasn’t been a big money maker. A not-for-profit helped fund the research that led to the approval of a new drug for neuroblastoma.
"Arterial kateter (Seldinger)" by Privatarchiv Foto von MrArifnajafov
Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report